Exxon Must Change Direction, Not Just Appoint New Board Candidates forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.
Patient Determinants for Histologic Diagnosis of Nonalcoholic Fatty Liver Disease in the Real World: A TARGET-NASH Study, aimed to determine patient characteristics that are predictive of having a diagnosis by biopsy versus a diagnosis using clinical criteria.
Analyzing 3,474 participants with NAFLD from August 2016 to March 2019, the study found 67% had not had a liver biopsy.
Analyzing 3,474 adult participants with nonalcoholic fatty liver disease (NAFLD) managed in usual clinical practice from August 2016 to March 2019, the study found 67% of the cohort had not had a liver biopsy. Predictive factors of having a diagnosis by biopsy included White race, female sex, diabetes, and elevated alanine aminotransferase (ALT). Overall, median age was 59 years, 59% were female, 75% White, and 66% obese. The most common comorbid conditions included cardiovascular disease (19%), osteoarthritis (10%), and mental health diagnoses or depression (49%). Of note, patients who had progressed to ci
2 months ago
Ondas to leverage Rogue’s expertise in marketing and sales to US Government and Defense Entities
NANTUCKET, Mass.–(BUSINESS WIRE)–Ondas Holdings Inc. (NASDAQ: ONDS), through its wholly owned subsidiary, Ondas Networks, announced today a strategic partnership with Rogue Industries to utilize Rogue’s procurement expertise and capabilities to market and sell Ondas’ MC-IoT platform to US government and defense markets.
“We are eager to leverage Rogue’s procurement expertise in the US government and defense markets, where successful contracting is a unique skill. We believe there is a significant market for our software-based radio platform based on prior interest from US government entities and defense contractors. Rogue provides the required experience to allow us to effectively market, sell, and support mission-critical government markets,” said Eric Brock, CEO of Ondas.
Coalition United for a Responsible Exxon (CURE) – Representing Stakeholders with over $2.2 Trillion in Assets – Calls for New Leadership and Strategy at Exxon
Letter to Board in support of multiple shareholder campaigns advocating change of governance and adoption of new, financially and strategically sustainable business plan
CURE”) was launched today with an open letter in support of meaningful change at ExxonMobil Corporation (NYSE: XOM) (“
Exxon” or the “
Company”). CURE represents a broad a spectrum of stakeholders focused on sustainability who are committed to delivering long-term returns that account for the realities of a changing energy sector. As of today, CURE’s over 135 members collectively represent over $2.2 trillion in assets. More details on the coalition can be found at CURExxon.org.
Target RWE Shares Weight Loss Data From Ongoing NASH Study
Real-world study shows only 32% of overweight or obese adults with NAFLD in the U.S. achieved 5% or more weight reduction
News provided by
Share this article
DURHAM, N.C., Feb. 2, 2021 /PRNewswire/
Target RWE, a leading real-world evidence (RWE) solutions company for the pharmaceutical and biotech industries, shared the latest data from the ongoing TARGET-NASH observational study, published in
The nonalcoholic steatohepatitis (NASH) study,
Weight Loss and Weight Regain in Usual Clinical Practice: Results from the TARGET-NASH Observational Cohort, analyzed 2,019 patients enrolled in the TARGET-NASH cohort in the United States over a median follow-up of 39 months. The baseline characteristics included one third of patients classified as obesity class 2/3, 38.6% of patients had diabetes, and approximately 50% had documentation of lifestyle modifications or diet recommendations.